Home/ Stocks/ CUE

Cue Biopharma, Inc.

CUE XNAS

$26.01 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$109.25M

About Cue Biopharma, Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 29 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$5.69M	$-5,178,000	$-1.08
FY 2025	$27.47M	$-26,602,000	$-0.28
Q3 2025	$2.15M	$-7,448,000	$-0.07
Q2 2025	$2.95M	$-8,482,000	$-0.09

TickerDaily Coverage

Stock Market Today, May 1, 2026: Mega Movers Dominate Week as CUE, BIYA Triple

Market News David Brooks · May 1, 2026

Friday, May 1, 2026 closes a wild week of outsized gains driven by a rotation into speculative...

Why Is Cue Biopharma (CUE) Stock Up 127.1% Today?

Market News Alex Chen · May 1, 2026

Cue Biopharma (CUE) stock exploded 127.1% on Friday, May 1, 2026, after the clinical-stage biotech...

View All Coverage →

Get CUE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cue Biopharma, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.